MTOR and cancer: Previous study has reported that targeting PI3KCI/Akt/mTOR signaling with inhibitors such as ATP-competitive compounds can improve cancer therapeutic effect because the catalytic sites of PI3KCI and mTOR share a high degree of sequence homology [30].